Volume Outcome Relationships and Effects

March 18, 2026 updated by: Methodist Health System

Volume Outcome Relationships and Effects of Adjuvant and Neoadjuvant Therapy in Mortality in Esophageal Cancer

This is a retrospective analysis to assess if high-volume hospital facilities experience greater or lesser rates of incidence in patients with esophageal cancer than low-volume facilities.

Study Overview

Status

Recruiting

Conditions

Detailed Description

This is a retrospective analysis to assess if high-volume hospital facilities experience greater or lesser rates of incidence in patients with esophageal cancer than low-volume facilities.

The relationship between volume and outcomes has been proven in pancreatic cancer. Similar to pancreatic cancer, esophageal cancer historically has a bad prognosis. Esophageal cancer is typically asymptomatic, resulting in an advanced stage at the time of diagnosis. Additionally, it also has a significantly high morbidity and mortality. Therefore, it is crucial to determine volume-outcome relationships in esophageal cancer. This study aims to elucidate what these findings may entail by evaluating the impact that the volume-outcome relationship has on treatment assessment in esophageal cancer patients.

The purpose of the study is to evaluate the outcomes of esophageal cancer resection in patients in high volume (more than 5 esophagectomy performed per year) and low volume (less than 5 esophagectomy performed per year) hospital facilities. Furthermore, this paper will assess the outcomes of neoadjuvant and adjuvant therapy in esophageal cancer.

Study Type

Observational

Enrollment (Estimated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • Texas
      • Richardson, Texas, United States, 75082
        • Recruiting
        • Methodist Richardson Medical Center
        • Contact:
        • Principal Investigator:
          • Dhiresh Jeyarajah, MD
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

The purpose of the study is to evaluate the outcomes of esophageal cancer resection in patients in high volume (more than 5 esophagectomy performed per year) and low volume (less than 5 esophagectomy performed per year) hospital facilities.

Description

Inclusion Criteria:

  • esophageal cancer

Exclusion Criteria:

  • No esophageal cancer

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Esophageal Cancer resection in patients in high volume (more than 5 esophagectomy performed per year) and low volume (less than 5 esophagectomy performed per year) hospital facilities
Time Frame: through study completion, up to 18 months
Retrospective analysis to assess if high-volume hospital facilities experience greater or lesser rates of incidence in patients with Esophageal Cancer than low-volume facilities
through study completion, up to 18 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Methodist Health System

Investigators

  • Principal Investigator: Dhiresh Jeyarajah, MD, Methodist Health System

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 15, 2020

Primary Completion (Estimated)

June 15, 2027

Study Completion (Estimated)

June 15, 2028

Study Registration Dates

First Submitted

April 27, 2022

First Submitted That Met QC Criteria

March 26, 2024

First Posted (Actual)

April 2, 2024

Study Record Updates

Last Update Posted (Actual)

March 20, 2026

Last Update Submitted That Met QC Criteria

March 18, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 037.HPB.2020.R

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe